Opinion: Reexamination of Failed DMD Trial a Much-Needed Reckoning for FibroGen
Biospace,
Pictured: Scientists analyze data on computers in a lab/iStock, gorodenkoff Despite finding initial success in Phase II…
Pictured: Scientists analyze data on computers in a lab/iStock, gorodenkoff Despite finding initial success in Phase II…
By David Bautz, PhD OTC:ICOTF | TSX:MSCL.V Satellos Bioscience Inc. (OTC:ICOTF)(TSX:MSCL.V) is a Canadian biotechnology company…
The Duchenne muscular dystrophy community's outrage over the $89,000 annual price tag announced for deflazacort (Emflaza)…
The annual $89,000 price-tag on an old corticosteroid, which was granted orphan drug status for treating Duchenne muscular…
The FDA has okayed deflazacort (Emflaza) for the treatment of Duchenne muscular dystrophy (DMD) in patients ages 5 and up, the…